Table 6.

Scenario analyses results for CAZ-AVI sequence vs. Meropenem sequence

Scenario	Incremental cost per QALY gained (% change from base case)
Base case	€ 15,574
Resistance adjustments
No adjustments	€ 27,626 (+ 77%)
Second-line efficacy
Assumed 100% response/cure rates in treatment	€ 30,614 (+ 97%)

CAZ-AVI = ceftazidime-avibactam; QALY = quality-adjusted life year.

CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem. Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem